Navigation Links
Anti-Toxoplasma Performance Panel from SeraCare Provides Broad Sample of New, Challenging Material
Date:7/16/2013

Milford, Massachusetts (PRWEB) July 16, 2013

SeraCare Life Sciences, a provider of high quality biological materials that help optimize diagnostic performance, reliability and repeatability across the IVD lifecycle, announced it has introduced a new AccuSet™ anti-Toxoplasma performance panel. This is the newest addition to the SeraCare line of performance panels designed to help IVD manufacturers effectively challenge new assays during development.

"The demand for Toxoplasma testing in the healthcare industry remains consistently high, requiring the development of new and rigorous testing platforms," said Kim Anderson, Product Manager, IVD Research Business Unit at SeraCare. Screening for the Toxoplasma gondii parasite is performed widely in pregnant women, infants born to infected women, and people with severely weakened or compromised immune systems, creating strong demand for rigorous anti-Toxoplasma assays.

SeraCare’s new AccuSet™ Anti-Toxoplasma gondii Mixed Titer Performance Panel (PTT202) helps IVD manufacturers respond to this market need. It comprises 21 members with a broad range of reactivity for IgG and IgM antibodies and contains donor material representing newer infections, which is critical for IVD manufacturers to effectively challenge new assays.

"Identifying donors who are newly infected with the Toxoplasma gondii parasite but already beginning to demonstrate antibody reactivity is inherently demanding," said Anderson. "SeraCare’s unrivaled sourcing network enabled us to find these donors and develop a panel that can provide our customers with the high degree of confidence they need when challenging the anti-Toxoplasma assays they are currently developing."

SeraCare’s new AccuSet™ Anti-Toxoplasma gondii Mixed Titer Performance Panel is available immediately worldwide. For more information, contact SeraCare Customer Service at 1-800-676-1881 or visit http://www.seracare.com.

About SeraCare Life Sciences, Inc.

SeraCare, a portfolio company of Linden Capital Partners, works with diagnostics researchers, IVD manufacturers and clinical laboratories to shape the future of medical diagnostics. Our innovative portfolio includes ACCURUN® quality controls, research panels, SeraCon™ processed plasma, specialty human blood products and Complete BioCollections™ materials. SeraCare helps bridge the gap between today’s diagnostic solutions and tomorrow’s emerging technologies for molecular diagnostics, next generation sequencing, and companion diagnostics. For more information, visit http://www.seracare.com.

About Linden Capital Partners

Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden currently has investments in middle market platforms in the products, distribution, and services segments of healthcare. For additional information about Linden, please refer to the firm's website at http://www.lindenllc.com.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10919460.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Arizona State University engineers aim to improve performance of technology in extreme environments
2. City of Mason and Top Gun Sales Performance Announce $4 Million Investment In New Corporate Headquarters
3. Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference
4. McLean Report on nanotechnology that may enhance medication delivery and improve MRI performance
5. New Daily Disposable Multifocal Contact Lenses from CooperVision Offer Comfort, Performance, Health, and Convenience to Fit Your Life
6. Maxx Performance Joins GreenPalm to Promote Sustainable Harvest of Palm Oil
7. Dyadic Demonstrates Industry-leading Biofuels Enzyme Performance
8. A KAIST research team has developed a high performance flexible solid state battery
9. Elsevier Launches New Journal: Performance Enhancement & Health
10. Nanoresonators might improve cell phone performance
11. New design could improve condenser performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)...  Dovetail Genomics™ LLC today announced that it has ... planned metagenomic genome assembly service. Richard Green , ... method in a talk on Friday, February 12 at ... in Orlando, Fla. ... difficult. Using its proprietary Chicago ™ ...
(Date:2/11/2016)... --  BioInformant announces the February 2016 release of ... Tools, and Technologies – Market Size, Segments, Trends, and ... The first and only market research ... has more than a decade of historical information on ... cell type. This powerful 175 page global strategic report ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... has announced a new agreement with Bankok,Thailand-based Global Stem Cells Network (GSCN) to ... in 15 Latin American countries, including Mexico, Costa Rica, Dominican Republic, Colombia, Argentina, ...
(Date:2/10/2016)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a ... Mitsui & Co. Ltd., its partner in the ... investing an additional CDN$25 million in the joint venture ... 30% to 40%.  Mitsui will also play a stronger ... Sarnia , providing dedicated resources alongside ...
Breaking Biology Technology:
(Date:2/3/2016)... , February 4, 2016 --> ... SEK 1,351.5 M (105.0), up 1,187% compared with fourth quarter of 2014. ... to SEK 517.6 M (loss: 30.0). Earnings per share increased ... was SEK 537.4 M (neg: 74.7). , ... Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% compared with 2014. ...
(Date:2/3/2016)... -- Vigilant Solutions announces today that the ... solved two recent hit-and-run cases with the ... Solutions. Brian Wenberg explains, "I was ... out of a convenience store and witnessed an elderly male back out ... his vehicle and leaving the scene.  In his statement ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS devices ... primarily focused on medical screening and diagnostic ... parameters. Wearable devices that facilitate and assure ... of movement are being bolstered through new ... biomedical signal acquisition coupled with wireless connectivity ...
Breaking Biology News(10 mins):